Long-term treatment with streptozocin/5-fluorouracil chemotherapy in patients with metastatic pancreatic neuroendocrine tumors Case series

被引:3
作者
Mueller, Christian [1 ]
Kreissl, Michael C. [2 ]
Klose, Silke [3 ]
Krause, Andreas [4 ]
Keitel, Verena [1 ]
Venerito, Marino [1 ]
机构
[1] Otto von Guericke Univ Hosp, Dept Gastroenterol Hepatol & Infect Dis, Leipziger Str 44, D-39120 Magdeburg, Germany
[2] Otto von Guericke Univ, Dept Radiol & Nucl Med, Div Nucl Med, Leipziger Str 44, Magdeburg, Germany
[3] Otto von Guericke Univ Hosp, Dept Nephrol & Hypertens, Diabet & Endocrinol, Leipziger Str 44, Magdeburg, Germany
[4] Esteve Pharmaceut GmbH, Dept Med & Sci, Hohenzollemdamm 150-151, Berlin, Germany
关键词
5-FU; chemotherapy; neuroendocrine tumor of the pancreas; streptozocin; STREPTOZOCIN PLUS FLUOROURACIL; CLINICAL-PRACTICE GUIDELINES; ENETS CONSENSUS GUIDELINES; PROGNOSTIC-FACTORS; NEOPLASMS; THERAPY; EPIDEMIOLOGY; 5-FLUOROURACIL; DOXORUBICIN; MANAGEMENT;
D O I
10.1097/MD.0000000000028610
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rationale: Pancreatic neuroendocrine tumors (pNETs) are rare entities representing 1% to 3% of all malignant pancreatic neoplasms. Current guidelines recommend a combination of streptozocin (STZ) and 5-fluorouracil (5-FU) for patients with metastatic well-differentiated pNETs requiring systemic therapy. The highest median progression-free survival rate reported in previous studies for this combination was 23 months (95% confidence interval 14.5-31.5). However, it remains unclear for how long this regimen can be safely administered. Patient concerns: We report about 3 therapy-naive patients with metastatic G2 (Ki67 10%-15%) pNETs treated with STZ/5-FU, that achieved sustained disease control for longer than 36 months. Diagnosis: Metastatic, well-differentiated G2 pNETs Interventions: Systemic chemotherapy with STZ/5-FU was administered until the disease progressed. In 1 case showing a mixed response, selected metastases of increasing size were additionally treated with surgery and brachytherapy. Outcomes: In our 3 patients with metastatic G2 pNETs, STZ/5-FU induced long-term disease control over 44, 42, and 95 months, respectively. No side effects that led to treatment discontinuation were observed. Lessons: In patients with metastatic G2 pNETs achieving disease control, STZ/5-FU can be safely administered.
引用
收藏
页数:6
相关论文
共 40 条
[1]   Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity [J].
Antonodimitrakis, Pantelis Clewemar ;
Sundin, Anders ;
Wassberg, Cecilia ;
Granberg, Dan ;
Skogseid, Britt ;
Eriksson, Barbro .
NEUROENDOCRINOLOGY, 2016, 103 (3-4) :345-353
[2]   Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors [J].
Arnold, Rudolf ;
Wilke, Alexandra ;
Rinke, Anja ;
Mayer, Christina ;
Kann, Peter Herbert ;
Klose, Klaus-Jochen ;
Scherag, Andre ;
Hahmann, Maik ;
Mueller, Hans-Helge ;
Barth, Peter .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2008, 6 (07) :820-827
[3]   Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours [J].
Dilz, Lisa-Marie ;
Denecke, Timm ;
Steffen, Ingo G. ;
Prasad, Vikas ;
von Weikersthal, Ludwig Fischer ;
Pape, Ulrich-Frank ;
Wiedenmann, Bertram ;
Pavel, Marianne .
EUROPEAN JOURNAL OF CANCER, 2015, 51 (10) :1253-1262
[4]   Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors [J].
Ekeblad, Sara ;
Sundin, Anders ;
Janson, Eva Tiensuu ;
Welin, Staffan ;
Granberg, Dan ;
Kindmark, Henrik ;
Dunder, Kristina ;
Kozlovacki, Gordana ;
Orlefors, Hakan ;
Sigurd, Mattias ;
Oberg, Kjell ;
Eriksson, Barbro ;
Skogseid, Britt .
CLINICAL CANCER RESEARCH, 2007, 13 (10) :2986-2991
[5]   Prognostic Factors and Survival in 324 Patients with Pancreatic Endocrine Tumor Treated at a Single Institution [J].
Ekeblad, Sara ;
Skogseid, Britt ;
Dunder, Kristina ;
Oberg, Kjell ;
Eriksson, Barbro .
CLINICAL CANCER RESEARCH, 2008, 14 (23) :7798-7803
[6]   STREPTOZOCIN PLUS FLUOROURACIL VERSUS DOXORUBICIN THERAPY FOR METASTATIC CARCINOID-TUMOR [J].
ENGSTROM, PF ;
LAVIN, PT ;
MOERTEL, CG ;
FOLSCH, E ;
DOUGLASS, HO .
JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (11) :1255-1259
[7]   NEUROENDOCRINE PANCREATIC TUMORS - CLINICAL PRESENTATION, BIOCHEMICAL AND HISTOPATHOLOGICAL FINDINGS IN 84 PATIENTS [J].
ERIKSSON, B ;
ARNBERG, H ;
LINDGREN, PG ;
LORELIUS, LE ;
MAGNUSSON, A ;
LUNDQVIST, G ;
SKOGSEID, B ;
WIDE, L ;
WILANDER, E ;
OBERG, K .
JOURNAL OF INTERNAL MEDICINE, 1990, 228 (02) :103-113
[8]   Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours [J].
Ezziddin, Samer ;
Khalaf, Feras ;
Vanezi, Maria ;
Haslerud, Torjan ;
Mayer, Karin ;
Al Zreiqat, Abdullah ;
Willinek, Winfried ;
Biersack, Hans-Juergen ;
Sabet, Amir .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (05) :925-933
[9]   Treatment of endocrine pancreatic tumors [J].
Fjällskog, ML ;
Janson, ET .
ACTA ONCOLOGICA, 2005, 44 (04) :329-338
[10]   Recommendations for management of patients with neuroendocrine liver metastases [J].
Frilling, Andrea ;
Modlin, Irvin M. ;
Kidd, Mark ;
Russell, Christopher ;
Breitenstein, Stefan ;
Salem, Riad ;
Kwekkeboom, Dik ;
Lau, Wan-Yee ;
Klersy, Catherine ;
Vilgrain, Valerie ;
Davidson, Brian ;
Siegler, Mark ;
Caplin, Martyn ;
Solcia, Enrico ;
Schilsky, Richard .
LANCET ONCOLOGY, 2014, 15 (01) :E8-E21